GRP78 in Glioma Progression and Therapy: Implications for Targeted Approaches

Area of Science:

• Neuro-oncology
• Molecular biology
• Cancer therapeutics

Background:

• Glioma is the most common primary malignant brain tumor, leading to significant mortality.
• Conventional therapies for glioma have limited efficacy and can cause toxicity.
• Glucose-regulated protein 78 (GRP78) is increasingly recognized for its role in glioma progression and therapeutic resistance.

Purpose of the Study:

• To review the biological characteristics of GRP78 in glioma.
• To elucidate the role of GRP78 in glioma pathophysiology and therapeutic resistance.
• To explore the potential of GRP78-targeted therapies for improved glioma treatment outcomes.

Main Methods:

• Literature review of studies on GRP78 in glioma.
• Analysis of GRP78's intracellular and cell surface functions.
• Examination of various GRP78-targeted therapeutic strategies.

Main Results:

• GRP78 is overexpressed in gliomas, promoting tumor growth, survival, and resistance.
• Aberrant GRP78 expression correlates with higher tumor grades and poorer prognosis.
• Targeting GRP78 via small molecules, antibodies, or CAR T-cells shows therapeutic potential.

Conclusions:

• GRP78 plays a critical role in glioma development and resistance to therapy.
• Targeting GRP78 presents a novel and promising strategy for glioma treatment.
• Combination therapies involving GRP78 inhibition may enhance clinical outcomes for glioma patients.